FDA Blocks Imports of Additional Olympus Endoscopes Over Quality Violations
On October 20, 2026, the U.S. Food and Drug Administration issued an updated alert barring shipments of several Olympus medical devices from entering the United States. The regulator placed the equipment under Import Alert 89-04 because Olympus Medical Systems Corporation failed to fix ongoing violations of quality system regulations at its Japanese manufacturing sites. The newly blocked items include enteroscopes and ingestible telemetric gastrointestinal capsule imaging systems, expanding an earlier import restriction established on June 24, 2025. This action affects devices such as bronchoscopes, laparoscopes, ureterorenoscopes, and automated endoscope reprocessors. For patients and clinicians, this decision does not mean an immediate halt to ongoing medical care. The FDA advised health care providers that existing devices already in clinics can remain in use if they work properly, pass leak tests, and are cleaned according to instructions. The agency cautioned against canceling scheduled procedures without providers first discussing the benefits and risks with their patients.
What was announced
The FDA updated a safety communication to announce that certain medical devices made in Japan by Olympus Medical Systems Corporation and its subsidiaries will be refused entry into the United States. Under Import Alert 89-04, the border agency will stop incoming shipments of specific models due to unresolved Quality System regulation violations.
This update on October 20, 2026, expands restrictions that the FDA first imposed on June 24, 2025. The list of blocked imports now includes enteroscopes, used to examine the small intestine, and ingestible telemetric gastrointestinal capsule imaging systems. These devices join a wider list of barred equipment: bronchoscopes for airway procedures, laparoscopes for abdominal surgeries, ureterorenoscopes for urinary tract interventions, and automated endoscope reprocessors. Five specific models were added in the latest notice, including the Endocapsule set and select bronchovideoscopes.
The import ban targets complete devices. It does not apply to accessories such as replacement parts, connectors, or single-use consumables.
What it means
Hospitals and clinics cannot buy new shipments of the listed Olympus devices from Japan. However, the FDA does not tell facilities to pull these tools from service immediately. Providers may keep using devices they already own, provided the equipment functions without problems and passes routine leak testing. Damaged instruments must be removed from use because they can harbor contamination.
Staff must follow manufacturer instructions to clean and reprocess each device and its accessories. Some of the affected models were subject to earlier recalls, which the FDA previously flagged as the most serious recall type. In those instances, providers must follow the manufacturer's specific recall notices. The agency also instructed doctors not to delay or cancel procedures without talking through the risks and benefits with their patients.
What the announcement does not tell us
The alert does not list the specific manufacturing failures that caused the import ban, citing only quality system violations. The agency does not state how many total units are currently in use across American hospitals.
Furthermore, the document does not estimate when Olympus might resolve the compliance issues or when the import alert might end. It also does not explain whether the ban will lead to equipment shortages for diagnostic procedures.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA MedWatch Safety Alerts’s own. Always check the original before acting on anything here.
The U.S. Food and Drug Administration (FDA) is alerting health care providers about import alerts for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation (Olympus) and its subsidiaries.
Opens www.fda.gov
More from FDA MedWatch Safety Alerts
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.